In NAFLD patients, low molecular weight fucoidan and high stability fucoxanthin (LMF-HSFx) as a therapeutic approach treatment for 24 weeks increased AdipoQ expression [81]. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.